Hinge Health (NYSE:HNGE) Earns Buy Rating from Analysts at Bank of America

Bank of America started coverage on shares of Hinge Health (NYSE:HNGE) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $42.00 price target on the stock.

Other analysts have also issued research reports about the stock. KeyCorp began coverage on shares of Hinge Health in a research report on Monday. They set an “overweight” rating and a $45.00 target price on the stock. Wall Street Zen raised Hinge Health to a “hold” rating in a research note on Monday, June 2nd. Needham & Company LLC assumed coverage on Hinge Health in a research report on Monday. They issued a “buy” rating and a $47.00 price objective for the company. Canaccord Genuity Group assumed coverage on Hinge Health in a research report on Monday. They set a “buy” rating and a $52.00 target price on the stock. Finally, Barclays assumed coverage on Hinge Health in a research note on Monday. They issued an “overweight” rating and a $43.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.00.

Hinge Health Price Performance

Shares of NYSE HNGE opened at $39.79 on Monday. Hinge Health has a 12 month low of $33.42 and a 12 month high of $43.80.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.